Dynacare will be upgrading to a new immunohematology instrumentation platform as of August 19th, 2024. Along with this upgrade there will be improvements to our processes including definition and communication of critical red cell antibody titres, reference lab referral when an unidentified antibody is encountered, and revision of our reporting comments. Additionally, Dynacare now offers maternal RHD genotyping for any pregnant patient identified as weak D phenotype.
Read More: Changes to Immunohematology Testing